Evidence map›Paper›PMID 30572474›Full record

ArticleMedicine2018

Dabigatran as an alternative for atrial thrombosis resistant to rivaroxaban: A case report.

Huan Sun, Qini Zhao, Yanjing Wang, Robert Lakin, Xueyan Liu, Ming Yu, Hongliang Yang, Dongmei Gao, Weiwei Chen, Guangyuan Gao and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huan SunCardiology Department, China-Japan Union Hospital of Jilin University.
Qini ZhaoCardiology Department, China-Japan Union Hospital of Jilin University.
Yanjing WangRadiology Department.
Robert LakinDepartment of Exercise Sciences, University of Toronto, Toronto, Canada.
Xueyan LiuCardiology Department, China-Japan Union Hospital of Jilin University.
Ming YuCardiology Department, China-Japan Union Hospital of Jilin University.
Hongliang YangCardiology Department, China-Japan Union Hospital of Jilin University.
Dongmei GaoUltrasound Department, China-Japan Union Hospital of Jilin University, Changchun, China.
Weiwei ChenCardiology Department, China-Japan Union Hospital of Jilin University.
Guangyuan GaoCardiology Department, China-Japan Union Hospital of Jilin University.
Mengjie YanCardiology Department, China-Japan Union Hospital of Jilin University.
Yuquan HeCardiology Department, China-Japan Union Hospital of Jilin University.
Ping YangCardiology Department, China-Japan Union Hospital of Jilin University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAnti-thrombosis therapy for atrial fibrillation (AF) management and stroke prevention is an important aspect of disease management. Novel oral anticoagulants (NOACs) are recommended by guidelines for AF management. However, if one can switch one NOAC to another when the former showed a poor effect has not been fully determined. PATIENT CONCERNS: A 52-year-old man was admitted to our center for heart failure and AF with a thrombus in the left atrium. DIAGNOSES: Cardiomyopathy was diagnosed by cardiac magnetic resonance (CMR) and echocardiography.

interventionsHe was prescribed rivaroxaban (20 mg daily) as treatment, and dabigatran (150 mg twice daily) was used when the thrombus was found to be non-response to rivaroxaban. OUTCOMES: The rivaroxaban did not diminish the atrial thrombus, and dabigatran was given instead which finally eliminated the thrombus. LESSONS: Individualized responsiveness to NOACs should be considered and paid more attention to during clinical practice.

Indexed as

AntithrombinsAtrial FibrillationDabigatranDrug ResistanceHeart AtriaHeart DiseasesHumansMaleMiddle AgedRivaroxabanThrombosisAntithrombinsDabigatranRivaroxaban

Identifiers

PMID30572474
PMCPMC6319865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.